Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Good financial results growth rate 19.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-10.0%)
  • Dividend yield for the last twelve months 3.4%
  • Free cash flow yield -2.6% (LTM)
  • Share price is 45.2% higher than minimum and 11.2% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (37.5x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (0.0%)192.45
year average price 188.21  


year start price 168.03 2024-07-15

min close price 164.99 2024-11-15

max close price 216.66 2025-03-10

current price 192.45 2025-07-14
Common stocks: 1 768 480 508

Dividend Yield:  3.4%
FCF Yield LTM: -2.6%
EV / LTM EBITDA: 37.5x
EV / EBITDA annualized: 25.9x
Last revenue growth (y/y):  +8.4%
Last growth of EBITDA (y/y):  +31.3%
Historical revenue growth:  +0.5%
Historical growth of EBITDA:  -20.4%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 340 344
Net Debt ($m): 64 755
EV (Enterprise Value): 405 099
EBITDA LTM ($m): 10 815
EV / LTM EBITDA: 37.5x
Price to Book: 56.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-12247wallst.com

3 No-Brainer Dividend Stocks to Buy In July

2025-07-12fool.com

3 Dividend Growth Stocks to Buy and Hold

2025-07-12fool.com

The Smartest Dividend Stocks to Buy With $300 Right Now

2025-07-11seekingalpha.com

A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025

2025-07-11fool.com

What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill

2025-07-10reuters.com

Glenmark Pharma jumps on unit's cancer licensing deal with AbbVie

2025-07-10benzinga.com

Why Is AbbVie Stock Trading Higher On Thursday?

2025-07-08cnbc.com

Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'

2025-07-08zacks.com

How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?

2025-07-07seekingalpha.com

2 ETFs To Prepare You For A Potential Recession
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data